December 20, 2006
Genta Restructures Operations to Focus on Future Initiatives
December 15, 2006
Genta Receives Non-Approvable Notice for Application of Genasense® in Patients with Chronic Lymphocytic Leukemia
December 11, 2006
Genasense® Trial in Chronic Lymphocytic Leukemia Shows Significant Impact of CT Scanning on Complete Remission
December 11, 2006
Randomized Trial of Genasense® in Advanced CLL Shows that Durable Clinical Benefit Correlates with Major Objective Response
December 8, 2006
Genta Provides Update on Analysis of Phase 3 Trial of Genasense in Older Patients with Acute Myelogenous Leukemia
December 4, 2006
Genta Clinical Programs Featured in Presentations at Annual Meeting of the American Society of Hematology
November 29, 2006
Genta Initiates Pilot Clinical Trial of Genasense® Plus Abraxane® and Temodar® As First-Line Therapy For Patients With Advanced Melanoma
November 20, 2006
Genta Incorporated To Present At The Lazard Capital Markets Third Annual Life Sciences Conference
November 9, 2006
Genasense® Shown Active Using Intermittent Dosing In Melanoma Preclinical Studies and In Combination with Abraxane®, Temodar®, and Kinase Inhibitors
November 8, 2006
New Analyses from Phase 3 Trial in CLL Identify Relapsed Patients who Maximally Benefit from Genasense® Treatment
November 7, 2006
Genta Incorporated Announces Third Quarter 2006 Financial Results and Corporate Highlights
November 6, 2006
Anti-Apoptosis Strategies for Cancer Treatment Reviewed At International Scientific Meeting
November 3, 2006
Genta Announces Receipt Of Notice Of Non-Compliance
November 2, 2006
Genta Incorporated To Present At The Rodman & Renshaw 8th Annual Healthcare Conference
October 31, 2006
Patient Accrual Completed Into Phase 3 Trial Of Genasense® In Patients With Acute Myeloid Leukemia
October 30, 2006
FDA Extends Review Period for Genasense® New Drug Application in Chronic Lymphocytic Leukemia
October 27, 2006
Scientific Presentations to Highlight Genta's Lead Anticancer Drug Genasense® in Patients with Hematologic Cancers and Solid Tumors
October 26, 2006
Genta Incorporated to Host Conference Call to Discuss Third Quarter Highlights and Financial Results
October 17, 2006
Genasense® Receives Orphan Drug Designation In Australia For Patients With Advanced Melanoma
October 13, 2006
Antisense Drug Targeting Oncogene Starts Phase 1 Trial in Patients with Advanced Cancer
October 6, 2006
Genta Receives Special Protocol Assessment from FDA for Randomized Trial of Genasense® Plus Chemotherapy in Chronic Lymphocytic Leukemia
September 25, 2006
Genta Announces Closing Of Common Stock Offering
September 19, 2006
Genta Announces Common Stock Offering Of Approximately $16 Million
September 19, 2006
Independent Analysis Of Eortc Trial Confirms Survival Impact Of Biomarker Identified In Phase 3 Trial Of Genasense® In Melanoma
September 15, 2006
Final Report Of Genasense Phase 3 Trial In Melanoma Published In Journal Of Clinical Oncology
September 6, 2006
FDA Advisory Committee Reviews Genasense® for Treatment of Chronic Lymphocytic Leukemia
September 5, 2006
Briefing Documents Posted for FDA Committee Review of Genasense® New Drug Application
August 18, 2006
Genta Revises Notice of Special Protocol Assessment for Confirmatory Trial of Genasense® Plus Chemotherapy in Chronic Lymphocytic Leukemia
August 8, 2006
Genta Incorporated Announces Second Quarter 2006 Financial Results and Corporate Highlights
August 1, 2006
Genta Incorporated to Host Conference Call to Discuss Second Quarter Highlights and Financial Results
July 27, 2006
Genta Announces FDA's Oncology Drug Advisory Committee Will Review Genasense® as Treatment for Chronic Lymphocytic Leukemia
July 26, 2006
Genta Receives Special Protocol Assessment from FDA for Confirmatory Trial of Genasense® Plus Chemotherapy in Chronic Lymphocytic Leukemia
July 21, 2006
Genta Announces Resignation of Jerome Groopman, M.D. from the Board of Directors
June 16, 2006
Proxy Resolutions for Genta Incorporated Approved at Annual Shareholders Meeting
June 8, 2006
Genta Announces Webcast of 2006 Annual Shareholders Meeting
June 3, 2006
Eradication of Minimal Residual Disease Reported in Patients with Chronic Lymphocytic Leukemia Treated with Chemotherapy plus Genasense®
May 30, 2006
Genasense® Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
May 10, 2006
Genta Incorporated To Present At Rodman & Renshaw 3rd Annual Global Healthcare Conference
May 9, 2006
Genta Incorporated Announces First Quarter 2006 Financial Results and Corporate Highlights
May 4, 2006
Genta Incorporated Hosts Conference Call To Discuss Firstquarter Highlights And Financial Results
April 5, 2006
Genasense® Mechanisms of Action with Chemotherapy and Radiation Featured at Cancer Research Meeting
March 23, 2006
Genta and Emisphere Technologies Enter into Exclusive Worldwide Licensing Agreement for Development of an Oral Gallium Compound
March 16, 2006
Genta Receives Designation As A Small/Medium Enterprise By The European Medicines Agency
March 13, 2006
Genta Announces Closing Of Common Stock Offering(2)
March 10, 2006
Genta Incorporated Announces Fourth Quarter and Year End 2005 Financial Results and Corporate Highlights
March 8, 2006
Genta Incorporated To Webcast Conference Call On Fourth Quarter And Year End 2005 Highlights And Financial Results
March 7, 2006
Genta incorporated to present at cowen & co. 26th annual healthcare conference
March 7, 2006
Genta Announces Common Stock Offering Of Approximately $40.8 Million
March 2, 2006
Randomized Trial Shows Ganite® Effective When Compared with A Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia
March 1, 2006
Genasense® New Drug Application Accepted for Review by FDA
February 15, 2006
Clinical Benefit Analysis of Genasense plus Chemotherapy Reported from Phase 3 Trial in Patients with Chronic Lymphocytic Leukemia
February 13, 2006
Genta Announces Dismissal of Shareholder Derivative Lawsuit in New Jersey State Court
February 7, 2006
Genta Incorporated to Present in Roundtable and Corporate Sessions at BIO CEO Investor Conference
February 2, 2006
Analysis of Genasense® Trial Confirms Major Efficacy Variables in Patients with Advanced Melanoma
February 1, 2006
Genasense® Marketing Authorization Application in Melanoma Accepted for Review by European Regulatory Agency
January 24, 2006
Subcutaneous Genasense® Trial Initiated in Patients with Solid Tumors
January 18, 2006
Genta Appoints Dr. Per Lindell as Vice President of Business Development
January 17, 2006
Genta Appoints Seasoned Pharma Executive, Lloyd Sanders, As Vice-President For Sales And Marketing
January 3, 2006
Genta Completes Marketing Authorization Application To Emea For Approval Of Genasense® Plus Chemotherapy For Patients With Advanced Melanoma
